Activators & Inhibitors

TRPC5-IN-2 is a potent inhibitor of TRPC5.

FWM-1 is a potent inhibitor of SARS-COV-2 NSP13 resolvase (free energy of binding: -328.6 kcal/mol).FWM-1 shows effective disruption of the binding of ATP to SARS-COV2 resolvase.

Rac)-Tanomastat ((Rac)-BAY 12-9566) is a racemate of Tanomastat. Tanomastat (BAY 12-9566) is an orally active, zinc carboxy-containing inhibitor of non-peptide biphenyl matrix metalloproteinases (MMPs) that inhibits MMP-2 (Ki: 11 nM), MMP-3 (Ki: 143 nM), MMP-9 (Ki: 301 nM), and MMP-13 (Ki: 1470 nM). In several experimental tumour models, Tanomastat exhibits anti-invasive and anti-metastatic effects.

Anti-hyperglycemic agent 1 is a potent inhibitor of alpha-glucosidase (IC50: 0.53 μM). anti-Hyperglycemic agent 1 can be used to study diabetes.

Antibacterial agent 48 is an antimicrobial agent that reduces the MIC of the antimicrobial agent Ceftazidime.

Trk-IN-11 (Compound 14h) is a potent inhibitor of TRK, with IC50 values of 1.4 nM for TrkA and 1.8 nM for TrkA G595R. Trk-IN-11 has shown research potential in cancer diseases.

Topoisomerase I inhibitor 6 (Compound 3) is a potent inhibitor of Topoisomerase I that traps the DNA-Top1 cleavage complex and has low cytotoxicity in non-cancerous cell lines. Research value.

TRK-IN-19 (Compound I-10 ) is a potent inhibitor of TRK with IC50 values of 1.1 nM for TRKA and 5.3 nM for TRKAG595R. TRK-IN-19 has shown potential research value in cancer disease.

Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual inhibitor of Dyrk1A (IC50: 177 nM) and α-synuclein aggregation (IC50: 10.5 μM). CNS permeability and neuroprotective activity.